A randomized, double-blind clinical trial that compared three widely used anticonvulsants for childhood absence epilepsy established that ethosuximide was the most appropriate first-line therapy for ...

Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

Levetiracetam reduces tonic-clonic seizures by over 77% in clinical studies. Ethosuximide is highly effective for absence seizures, especially in children. Valproate remains the gold standard for ...

Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.

Imagine slipping in and out of consciousness hundreds of times per day, staying awake the whole time but having no sense of awareness during these lapses. In children with absence epilepsy, these ...

Scientists have discovered a neurological origin for absence seizures--a type of seizure characterized by very short periods of lost consciousness in which people appear to stare blankly at nothing.

“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...